Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Gross Margin (2016 - 2025)

Ocular Therapeutix has reported Gross Margin over the past 12 years, most recently at 87.97% for Q4 2025.

  • Quarterly results put Gross Margin at 87.97% for Q4 2025, down 483.0% from a year ago — trailing twelve months through Dec 2025 was 40.76% (down 905.0% YoY), and the annual figure for FY2025 was 87.35%, down 383.0%.
  • Gross Margin for Q4 2025 was 87.97% at Ocular Therapeutix, up from 10.01% in the prior quarter.
  • Over the last five years, Gross Margin for OCUL hit a ceiling of 276.55% in Q4 2022 and a floor of 147.65% in Q4 2023.
  • Median Gross Margin over the past 5 years was 31.36% (2022), compared with a mean of 57.64%.
  • Biggest five-year swings in Gross Margin: surged 32055bps in 2021 and later plummeted -42420bps in 2023.
  • Ocular Therapeutix's Gross Margin stood at 275.89% in 2021, then grew by 0bps to 276.55% in 2022, then tumbled by -153bps to 147.65% in 2023, then surged by 163bps to 92.8% in 2024, then dropped by -5bps to 87.97% in 2025.
  • The last three reported values for Gross Margin were 87.97% (Q4 2025), 10.01% (Q3 2025), and 85.56% (Q2 2025) per Business Quant data.